New bispecific CAR-T treatment of malignant hematological tumors
- Did Cloud Seeding Unleash a Deluge in Dubai?
- Scientists Identify Gut Bacteria and Metabolites that Lower Diabetes Risk
- OpenAI’s Model Matches Doctors in Assessing Eye Conditions
- UK: A Smoke-Free Generation by Banning Sales to Those Born After 2009
- Deadly Mutation: A New Monkeypox Variant Emerges in the DRC
- EPA Announces First-Ever Regulation for “Forever Chemicals” in Drinking Water
The complete remission rate is 80%! New bispecific CAR-T treatment of malignant hematological tumors.,The complete remission rate is 80%!
New bispecific CAR-T treatment of malignant hematological tumors. New bispecific CAR-T therapy for malignant hematological tumors (blood cancer) has a complete remission rate of 80%.
As we all know, the results of CAR-T in the treatment of malignant hematological tumors are obvious to all. This is all due to the progenitor target of hematological tumors-CD19, which exists only in tumor cells and not in normal cells. In the cell. Therefore, this target can be used to lead CAR-T cells to find and destroy cancer cells in tumor treatment.
At present, the United States has approved four CAR-T therapies for certain lymphomas that all target CD19.
CAR-T clinical trial
Despite its amazing efficacy, the therapy still has some limitations, including disease recurrence. For example, about half of B-cell lymphoma patients relapse within six months after starting CAR T cell therapy. This is due to the lack of CAR T cell persistence on the tumor and the down-regulation of the target antigen CD19. Once recurrence, the patient’s treatment options are very limited and the prognosis is poor.
At the AACR conference in 2021, Dr. Sanaz Ghafouri, a researcher in hematology and oncology at UCLA Medical Center, announced a new research result that caused a huge sensation.
They developed a new type of bispecific CAR T cell that can target two tumor antigens CD19/CD20 at the same time. This is the first bispecific CAR-T cell therapy developed and tested on patients using primitive memory T cells. This method may increase the persistence and expansion of CAR T cells in patients, while avoiding tumors. Relapse caused by loss of antigen.
This trial enrolled 5 patients with B-cell malignancies with positive expression of both CD19 and CD20 tumor antigens. These patients received an average of 4 therapies before. Naive memory T cells are extracted from each patient, engineered to express anti-CD19/CD20 CAR, amplified and then injected back into the patient.
After a median follow-up of 13 months, 4 out of 5 patients experienced complete remission (80%)!
Complete remission rate of bispecific CAR-T therapy
It is worth mentioning that there was no dose-limiting toxicity or neurotoxicity in any patient. All patients experience grade 1 cytokine release syndrome. Therefore, this new type of CAR-T therapy has excellent safety and provides the possibility of long-term sustained relief for this idiopathic disease!
We look forward to creating CAR-T treatment technologies with better curative effects and lower side effects on a global scale to benefit mankind. In addition, I can tell you the good news that the first CAR-T therapy in China will be approved in the near future! For information on listing and clinical recruitment, please call the Global Oncology Network Medical Department for consultation 4006667998
(source:internet, reference only)
Disclaimer of medicaltrend.org
